Search

Your search keyword '"Garderet, L."' showing total 509 results
Start Over Author "Garderet, L." Publication Year Range Last 50 years
509 results on '"Garderet, L."'

1. Continuous and differential improvement in worldwide access to hematopoietic cell transplantation: activity has doubled in a decade with a notable increase in unrelated and non-identical related donors.

Author

Atsuta, Y, Baldomero, H, Neumann, D, Sureda, A, DeVos, JD, Iida, M, Karduss, A, Purtill, D, Elhaddad, AM, Bazuaye, NG, Bonfim, C, De la Camara, R, Chaudhri, NA, Ciceri, F, Correa, C, Frutos, C, Galeano, S, Garderet, L, Gonzalez-Ramella, O, Greco, R, Hamad, N, Hazenberg, MD, Horowitz, MM, Kalwak, K, Ko, B-S, Kodera, Y, Koh, MB, Liu, K, McLornan, DP, Moon, JH, Neven, B, Okamoto, S, Pasquini, MC, Passweg, JR, Paulson, K, Rondelli, D, Ruggeri, A, Seber, A, Snowden, JA, Srivastava, A, Szer, J, Weisdorf, D, Worel, N, Greinix, H, Saber, W, Aljurf, M, Niederwieser, D, Atsuta, Y, Baldomero, H, Neumann, D, Sureda, A, DeVos, JD, Iida, M, Karduss, A, Purtill, D, Elhaddad, AM, Bazuaye, NG, Bonfim, C, De la Camara, R, Chaudhri, NA, Ciceri, F, Correa, C, Frutos, C, Galeano, S, Garderet, L, Gonzalez-Ramella, O, Greco, R, Hamad, N, Hazenberg, MD, Horowitz, MM, Kalwak, K, Ko, B-S, Kodera, Y, Koh, MB, Liu, K, McLornan, DP, Moon, JH, Neven, B, Okamoto, S, Pasquini, MC, Passweg, JR, Paulson, K, Rondelli, D, Ruggeri, A, Seber, A, Snowden, JA, Srivastava, A, Szer, J, Weisdorf, D, Worel, N, Greinix, H, Saber, W, Aljurf, M, and Niederwieser, D

Abstract

Promoting access to and excellence in hematopoietic cell transplantation (HCT) by collecting and disseminating data on global HCT activities is one of the principal activities of the Worldwide Network for Blood and Marrow Transplantation, a non-Governmental organization in working relations with the World Health Organization. HCT activities are recorded annually by member societies, national registries and individual centers including indication, donor type (allogeneic/autologous), donor match and stem cell source (bone marrow/peripheral blood stem cells/cord blood). In 2018, 1,768 HCT teams in 89 countries (six WHO regions) reported 93,105 (48,680 autologous and 44,425 allogeneic) HCT. Major indications were plasma cell disorders and lymphoma for autologous, and acute leukemias and MDS/MPN for allogeneic HCT. HCT number increased from 48,709 in 2007. Notable increases were seen for autoimmune diseases in autologous and hemoglobinopathies in allogeneic HCT. The number of allogeneic HCT more than doubled with significant changes in donor match. While HCT from HLA identical siblings has seen only limited growth, HCT from non-identical related donors showed significant increase worldwide. Strongest correlation between economic growth indicator of gross national income/capita and HCT activity/ten million population was observed for autologous HCT (r=0.79). HCT from unrelated donors showed strong correlation (r=0.68), but only moderate correlation (r=0.51) was detected from related donors. The use of HCT doubled in about a decade worldwide at different speed and with significant changes regarding donor match as a sign of improved access to HCT worldwide. Although narrowing, significant gaps remain between developing and non-developing countries.

Published
2024

2. Second primary malignancies in multiple myeloma: an overview and IMWG consensus

Author

Musto, P., Anderson, K.C., Attal, M., Richardson, P.G., Badros, A., Hou, J., Comenzo, R., Du, J., Durie, B.G.M., San Miguel, J., Einsele, H., Chen, W.M., Garderet, L., Pietrantuono, G., Hillengass, J., Kyle, R.A., Moreau, P., Lahuerta, J.J., Landgren, O., Ludwig, H., Larocca, A., Mahindra, A., Cavo, M., Mazumder, A., McCarthy, P.L., Nouel, A., Rajkumar, S.V., Reiman, A., Riva, E., Sezer, O., Terpos, E., Turesson, I., Usmani, S., Weiss, B.M., and Palumbo, A.

Published
2017
Full Text
View/download PDF

3. Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myeloma

Author

Fouquet, G., Pegourie, B., Macro, M., Petillon, M.O., Karlin, L., Caillot, D., Roussel, M., Arnulf, B., Mathiot, C., Marit, G., Kolb, B., Stoppa, A.M., Brechiniac, S., Richez, V., Rodon, P., Banos, A., Wetterwald, M., Garderet, L., Royer, B., Hulin, C., Benbouker, L., Decaux, O., Escoffre-Barbe, M., Fermand, J.P., Attal, M., Avet-Loiseau, H., Moreau, P., Facon, T., and Leleu, X.

Published
2016
Full Text
View/download PDF

5. Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party

Author

Sobh, M, Michallet, M, Gahrton, G, Iacobelli, S, van Biezen, A, Schönland, S, Petersen, E, Schaap, N, Bonifazi, F, Volin, L, Meijer, E, Niederwieser, D, El-Cheikh, J, Tabrizi, R, Fegeux, N, Finke, J, Bunjes, D, Cornelissen, J, Einsele, H, Bruno, B, Potter, M, Fanin, R, Mohty, M, Garderet, L, and Kröger, N

Published
2016
Full Text
View/download PDF

6. Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group

Author

Laubach, J, Garderet, L, Mahindra, A, Gahrton, G, Caers, J, Sezer, O, Voorhees, P, Leleu, X, Johnsen, H E, Streetly, M, Jurczyszyn, A, Ludwig, H, Mellqvist, U-H, Chng, W-J, Pilarski, L, Einsele, H, Hou, J, Turesson, I, Zamagni, E, Chim, C S, Mazumder, A, Westin, J, Lu, J, Reiman, T, Kristinsson, S, Joshua, D, Roussel, M, O'Gorman, P, Terpos, E, McCarthy, P, Dimopoulos, M, Moreau, P, Orlowski, R Z, Miguel, J S, Anderson, K C, Palumbo, A, Kumar, S, Rajkumar, V, Durie, B, and Richardson, P G

Published
2016
Full Text
View/download PDF

7. 32nd International Austrian Winter Symposium: Zell am See, the Netherlands. 20-23 January 2016

Author

Langsteger, W, Rezaee, A, Loidl, W, Geinitz, HS, Fitz, F, Steinmair, M, Broinger, G, Pallwien-Prettner, L, Beheshti, M, Imamovic, L, Beheshti, M, Rendl, G, Hackl, D, Tsybrovsky, O, Steinmair, M, Emmanuel, K, Moinfar, F, Pirich, C, Langsteger, W, Bytyqi, A, Karanikas, G, Mayerhöfer, M, Koperek, O, Niederle, B, Hartenbach, M, Beyer, T, Herrmann, K, Czernin, J, Rausch, I, Rust, P, DiFranco, MD, Lassen, M, Stadlbauer, A, Mayerhöfer, ME, Hartenbach, M, Hacker, M, Beyer, T, Binzel, K, Magnussen, R, Wei, W, Knopp, MU, Flanigan, DC, Kaeding, C, Knopp, MV, Leisser, A, Nejabat, M, Hartenbach, M, Kramer, G, Krainer, M, Hacker, M, Haug, A, Lehnert, Wencke, Schmidt, Karl, Kimiaei, Sharok, Bronzel, Marcus, Kluge, Andreas, Wright, CL, Binzel, K, Zhang, J, Wuthrick, Evan, Maniawski, Piotr, Knopp, MV, Blaickner, M, Rados, E, Huber, A, Dulovits, M, Kulkarni, H, Wiessalla, S, Schuchardt, C, Baum, RP, Knäusl, B, Georg, D, Bauer, M, Wulkersdorfer, B, Wadsak, W, Philippe, C, Haslacher, H, Zeitlinger, M, Langer, O, Bauer, M, Feldmann, M, Karch, R, Wadsak, W, Zeitlinger, M, Koepp, MJ, Asselin, M-C, Pataraia, E, Langer, O, Zeilinger, M, Philippe, C, Dumanic, M, Pichler, F, Pilz, J, Hacker, M, Wadsak, W, Mitterhauser, M, Nics, L, Steiner, B, Hacker, M, Mitterhauser, M, Wadsak, W, Traxl, A, Wanek, Thomas, Kryeziu, Kushtrim, Mairinger, Severin, Stanek, Johann, Berger, Walter, Kuntner, Claudia, Langer, Oliver, Mairinger, S, Wanek, T, Traxl, A, Krohn, M, Stanek, J, Filip, T, Sauberer, M, Kuntner, C, Pahnke, J, Langer, O, Svatunek, D, Denk, C, Wilkovitsch, M, Wanek, T, Filip, T, Kuntner-Hannes, C, Fröhlich, J, Mikula, H, Denk, C, Svatunek, D, Wanek, T, Mairinger, S, Stanek, J, Filip, T, Fröhlich, J, Mikula, H, Kuntner-Hannes, C, Balber, T, Singer, J, Fazekas, J, Rami-Mark, C, Berroterán-Infante, N, Jensen-Jarolim, E, Wadsak, W, Hacker, M, Viernstein, H, Mitterhauser, M, Denk, C, Svatunek, D, Sohr, B, Mikula, H, Fröhlich, J, Wanek, T, Kuntner-Hannes, C, Filip, T, Pfaff, S, Philippe, C, Mitterhauser, M, Hartenbach, M, Hacker, M, Wadsak, W, Wanek, T, Halilbasic, E, Visentin, M, Mairinger, S, Stieger, B, Kuntner, C, Trauner, M, Langer, O, Lam, P, Aistleitner, M, Eichinger, R, Artner, C, Eidherr, H, Vraka, C, Haug, A, Mitterhauser, M, Nics, L, Hartenbach, M, Hacker, M, Wadsak, W, Kvaternik, H, Müller, R, Hausberger, D, Zink, C, Aigner, RM, Cossío, U, Asensio, M, Montes, A, Akhtar, S, te Welscher, Y, van Nostrum, R, Gómez-Vallejo, V, Llop, J, VandeVyver, F, Barclay, T, Lippens, N, Troch, M, Hehenwarter, L, Egger, B, Holzmannhofer, J, Rodrigues-Radischat, M, Pirich, C, Pötsch, N, Rausch, I, Wilhelm, D, Weber, M, Furtner, J, Karanikas, G, Wöhrer, A, Mitterhauser, M, Hacker, M, Traub-Weidinger, T, Cassou-Mounat, T, Balogova, S, Nataf, V, Calzada, M, Huchet, V, Kerrou, K, Devaux, J-Y, Mohty, M, Garderet, L, Talbot, J-N, Stanzel, S, Pregartner, G, Schwarz, T, Bjelic-Radisic, V, Liegl-Atzwanger, B, Aigner, R, Stanzel, S, Quehenberger, F, Aigner, RM, Marković, A Koljević, Janković, Milica, Jerković, V Miler, Paskaš, M, Pupić, G, Džodić, R, Popović, D, Fornito, MC, Familiari, D, Koranda, P, Polzerová, H, Metelková, I, Henzlová, L, Formánek, R, Buriánková, E, Kamínek, M, Thomson, WH, Lewis, C, Thomson, WH, O’Brien, J, James, G, Notghi, A, Huber, H, Stelzmüller, I, Wunn, R, Mandl, M, Fellner, F, Lamprecht, B, Gabriel, M, Fornito, MC, Leonardi, G, Thomson, WH, O’Brien, J, James, G, Hudzietzová, J, Sabol, J, and Fülöp, M

Published
2016
Full Text
View/download PDF

9. Complications of Autologous Stem Cell Transplantation in Multiple Myeloma: Results from the CALM Study

Author

Waszczuk-Gajda, A., Penack, O., Sbianchi, G., Koster, L, Blaise, D., Reményi, P., Russell, N., Ljungman, P., Trneny, M., Mayer, J., Iacobelli, S., Kobbe, G., Scheid, C., Apperley, J., Touzeau, C., Lenhoff, S., Jantunen, E., Anagnostopoulos, A., Paris, L., Browne, P., Thieblemont, C., Schaap, N.P., Sierra, J., Yakoub-Agha, I., Garderet, L., Styczynski, J., Schoemans, H., Moiseev, I., Duarte, R.F., Peric, Z., Montoto, S., Biezen, A. van, Mikulska, M., Aljurf, M., Ruutu, T., Kröger, N., Morris, C., Koenecke, C., Schoenland, S., Basak, G.W., Waszczuk-Gajda, A., Penack, O., Sbianchi, G., Koster, L, Blaise, D., Reményi, P., Russell, N., Ljungman, P., Trneny, M., Mayer, J., Iacobelli, S., Kobbe, G., Scheid, C., Apperley, J., Touzeau, C., Lenhoff, S., Jantunen, E., Anagnostopoulos, A., Paris, L., Browne, P., Thieblemont, C., Schaap, N.P., Sierra, J., Yakoub-Agha, I., Garderet, L., Styczynski, J., Schoemans, H., Moiseev, I., Duarte, R.F., Peric, Z., Montoto, S., Biezen, A. van, Mikulska, M., Aljurf, M., Ruutu, T., Kröger, N., Morris, C., Koenecke, C., Schoenland, S., and Basak, G.W.

Abstract

Contains fulltext : 251609.pdf (Publisher’s version ) (Open Access), BACKGROUND: The main goal of this post hoc analysis of the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study was to evaluate the rate of short- and long-term infectious and non-infectious complications occurring after ASCT in patients with multiple myeloma (MM). METHODS: The analysis included all patients with MM from the CALM study who underwent ≥1 ASCT. The primary endpoint of the analysis was to determine the rate of infectious and non-infectious complications after ASCT and to compare them in three time periods: 0-100 days, 101 days-1 year, and >1 year after the first transplant. RESULTS: The analysis included a total of 3552 patients followed up for a median of 56.7 months (range 0.4-108.1). Complication rates decreased with the time from ASCT with 24.85 cases per 100 patient-years from day 0 to 100 days after the transplant, and <2.31 cases per 100 patient-years from the 101st day. At 100 days after ASC T, 45.7% of patients had complications, with infectious events being twice as frequent as non-infectious complications. Bacterial infections (6.5 cases per 100 patient-years, 95% CI: 6.1-7.0) and gastrointestinal complications (4.7 cases per 100 patient-years, 95% CI: 4.3-5.1) were the most common early events. The pattern of complications changed with time from ASCT. The presence of complications after ASCT was not associated with overall survival. CONCLUSIONS: Our data provide a solid basis for comparing ASCT-related complications to those caused by emerging treatments in multiple myeloma, such as CAR T-cell therapy and other immunotherapies.

Published
2022

13. Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group

Author

Raje, N.S. Anaissie, E. Kumar, S.K. Lonial, S. Martin, T. Gertz, M.A. Krishnan, A. Hari, P. Ludwig, H. O'Donnell, E. Yee, A. Kaufman, J.L. Cohen, A.D. Garderet, L. Wechalekar, A.F. Terpos, E. Khatry, N. Niesvizky, R. Yi, Q. Joshua, D.E. Saikia, T. Leung, N. Engelhardt, M. Mothy, M. Branagan, A. Chari, A. Reiman, A.J. Lipe, B. Richter, J. Rajkumar, S.V. Miguel, J.S. Anderson, K.C. Stadtmauer, E.A. Prabhala, R.H. McCarthy, P.L. Munshi, N.C.

Abstract

Infection remains the leading cause of morbidity and mortality in patients with multiple myeloma because of the cumulative effect of disease, treatment, and host-related factors. Given that infectious risk is cumulative through the course of the disease, preventing infections is paramount. Optimal preventive strategies include vaccination against common pathogens, antimicrobial prophylaxis, infection control measures, and immunoglobulin replacement in a small subset of patients; however, there are no universally accepted guidelines for infection prevention. This Review provides a consensus statement from a panel of 36 experts with global representation, which was convened by The International Myeloma Society to review existing literature and current guidelines, address issues associated with the risk of infection and prevention of infectious complications in multiple myeloma in the context of emerging therapies, and offer recommendations for preventing these complications. © 2022 Elsevier Ltd

Published
2022

14. Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation

Author

Mohty, M, Hübel, K, Kröger, N, Aljurf, M, Apperley, J, Basak, G W, Bazarbachi, A, Douglas, K, Gabriel, I, Garderet, L, Geraldes, C, Jaksic, O, Kattan, M W, Koristek, Z, Lanza, F, Lemoli, R M, Mendeleeva, L, Mikala, G, Mikhailova, N, Nagler, A, Schouten, H C, Selleslag, D, Suciu, S, Sureda, A, Worel, N, Wuchter, P, Chabannon, C, and Duarte, R F

Published
2014
Full Text
View/download PDF

15. Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients

Author

Hebraud, B, Leleu, X, Lauwers-Cances, V, Roussel, M, Caillot, D, Marit, G, Karlin, L, Hulin, C, Gentil, C, Guilhot, F, Garderet, L, Lamy, T, Brechignac, S, Pegourie, B, Jaubert, J, Dib, M, Stoppa, A-M, Sebban, C, Fohrer, C, Fontan, J, Fruchart, C, Macro, M, Orsini-Piocelle, F, Lepeu, G, Sohn, C, Corre, J, Facon, T, Moreau, P, Attal, M, and Avet-Loiseau, H

Published
2014
Full Text
View/download PDF

18. Folliculotropic T-cell infiltrates associated with B-cell chronic lymphocytic leukaemia or MALT lymphoma may reveal either true mycosis fungoides or pseudolymphomatous reaction: seven cases and review of the literature

Author

Ingen-Housz-Oro, S., Franck, N., Beneton, N., Fauconneau, A., Do-Pham, G., Carlotti, A., Petit, T., Liolios, I., Bara, C., Carpentier, H., Storelli, D., Prophette, B., Garderet, L., Haioun, C., Petit, E., Delfau-Larue, M.-H., Vergier, B., Chosidow, O., Beylot-Barry, M., and Ortonne, N.

Published
2015
Full Text
View/download PDF

19. Reduced intensity-conditioned allogeneic stem cell transplantation for multiple myeloma relapsing or progressing after autologous transplantation: a study by the European Group for Blood and Marrow Transplantation

Author

Auner, H W, Szydlo, R, van Biezen, A, Iacobelli, S, Gahrton, G, Milpied, N, Volin, L, Janssen, J, Nguyen Quoc, S, Michallet, M, Schoemans, H, el Cheikh, J, Petersen, E, Guilhot, F, Schönland, S, Ahlberg, L, Morris, C, Garderet, L, de Witte, T, and Kröger, N

Published
2013
Full Text
View/download PDF

22. Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network

Author

Ludwig, H. Boccadoro, M. Moreau, P. San-Miguel, J. Cavo, M. Pawlyn, C. Zweegman, S. Facon, T. Driessen, C. Hajek, R. Dimopoulos, M.A. Gay, F. Avet-Loiseau, H. Terpos, E. Zojer, N. Mohty, M. Mateos, M.-V. Einsele, H. Delforge, M. Caers, J. Weisel, K. Jackson, G. Garderet, L. Engelhardt, M. van de Donk, N. Leleu, X. Goldschmidt, H. Beksac, M. Nijhof, I. Abildgaard, N. Bringhen, S. Sonneveld, P.

Abstract

Vaccination is one of the most successful medical interventions that has saved the life of millions of people. Vaccination is particularly important in patients with multiple myeloma, who have an increased risk of infections due to the disease-inherent immune suppression, and because of the immune suppressive effects of therapy. Hence, all appropriate measures should be exploited, to elicit an effective immune response to common pathogens like influenza, pneumococci, varicella zoster virus, and to those bacteria and viruses (haemophilus influenzae, meningococci, and hepatitis) that frequently may pose a significant risk to patients with multiple myeloma. Patients after autologous, and specifically after allogeneic transplantation have severely reduced antibody titers, and therefore require a broader spectrum of vaccinations. Response to vaccination in myeloma often is less vigorous than in the general population, mandating either measurement of the postvaccination antibody titers and/or repeating the vaccination. Here, we compile the existing data on vaccination in multiple myeloma and provide recommendations for clinical practice. © 2020, The Author(s).

Published
2021

23. Recent Advancements in Hematology: Knowledge, Methods and Dissemination, Part 2

Author

Corre, J, Sabbah, M, Schjesvold, F, Zeidan, AM, Buccisano, F, Sallman, D, Mazzucato, M, Madden, LA, Martini, M, Van Breda, E, Dolcetti, R, Busca, A, Cook, G, Onida, F, Versari, A, Kiladjian, J-J, Walter, RB, Garderet, L, Robin, M, Signore, A, Corre, J, Sabbah, M, Schjesvold, F, Zeidan, AM, Buccisano, F, Sallman, D, Mazzucato, M, Madden, LA, Martini, M, Van Breda, E, Dolcetti, R, Busca, A, Cook, G, Onida, F, Versari, A, Kiladjian, J-J, Walter, RB, Garderet, L, Robin, M, and Signore, A

Abstract

Recent Advancements in Hematology: Knowledge, Methods and Dissemination is a series of commentary article which is published on a biannual basis by the editorial board of the journal Hemato [...]

Published
2021

24. Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network

Author

Ludwig, H, Boccadoro, M, Moreau, P, San-Miguel, J, Cavo, M, Pawlyn, C, Zweegman, S, Facon, T, Driessen, C, Hajek, R, Dimopoulos, MA, Gay, F, Avet-Loiseau, H, Terpos, E, Zojer, N, Mohty, M, Mateos, MV, Einsele, H, Delforge, M, Caers, J, Weisel, K, Jackson, G, Garderet, L, Engelhardt, M, van de Donk, N, Leleu, X, Goldschmidt, H, Beksac, M, Nijhof, I, Abildgaard, N, Bringhen, S, Sonneveld, Pieter, Ludwig, H, Boccadoro, M, Moreau, P, San-Miguel, J, Cavo, M, Pawlyn, C, Zweegman, S, Facon, T, Driessen, C, Hajek, R, Dimopoulos, MA, Gay, F, Avet-Loiseau, H, Terpos, E, Zojer, N, Mohty, M, Mateos, MV, Einsele, H, Delforge, M, Caers, J, Weisel, K, Jackson, G, Garderet, L, Engelhardt, M, van de Donk, N, Leleu, X, Goldschmidt, H, Beksac, M, Nijhof, I, Abildgaard, N, Bringhen, S, and Sonneveld, Pieter

Abstract

Vaccination is one of the most successful medical interventions that has saved the life of millions of people. Vaccination is particularly important in patients with multiple myeloma, who have an increased risk of infections due to the disease-inherent immune suppression, and because of the immune suppressive effects of therapy. Hence, all appropriate measures should be exploited, to elicit an effective immune response to common pathogens like influenza, pneumococci, varicella zoster virus, and to those bacteria and viruses (haemophilus influenzae, meningococci, and hepatitis) that frequently may pose a significant risk to patients with multiple myeloma. Patients after autologous, and specifically after allogeneic transplantation have severely reduced antibody titers, and therefore require a broader spectrum of vaccinations. Response to vaccination in myeloma often is less vigorous than in the general population, mandating either measurement of the postvaccination antibody titers and/or repeating the vaccination. Here, we compile the existing data on vaccination in multiple myeloma and provide recommendations for clinical practice.

Published
2021

29. REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANT IN PATIENTS WITH MULTIPLE MYELOMA: A COMPARISON OF TANDEM AUTO-ALLOGRAFT TO EARLY REDUCED INTENSITY ALLOGRAFT AS UPFRONT TRANSPLANT: AN EBMT ANALYSIS ON BEHALF OF THE PLASMA CELL DISORDERS: PH-O144

Author

Sahebi, F., Iacobelli, S., Van Biezen, A., Volin, L., Dreger, P., Michallet, M., Ljungman, P. T., Morris, C. TCM, Schonland, S., de Witte, T., Garderet, L., Henseler, A., Schaap, N. P. M., López-Corral, L., Poire, X., Passweg, J., Hamljadi, R. M., Kroeger, N., and Gahrton, G.

Published
2014

30. HIGH DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) INDUCES DURABLE REMISSIONS IN PATIENTS WITH POEMS SYNDROME: A RETROSPECTIVE STUDY OF THE PLASMA CELL DISORDERS SUBCOMMITTEE OF THE CHRONIC MALIGNANCY WORKING PARTY OF THE EBMT: PH-O134

Author

Cook, G., Garderet, L., Iacobelli, S., van Biezen, A., Hoek, J., Rovira, M., Byrne, J., Bordessoule, D., Leone, G., Nagler, A., Castagna, L., Cook, M., Legros, L., Ossenkoppele, G., Leblond, V., Morris, T., and Kroger, N.

Published
2014

31. Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials

Author

Moreau, P, Attal, M, Garban, F, Hulin, C, Facon, T, Marit, G, Michallet, M, Doyen, C, Leyvraz, S, Mohty, M, Wetterwald, M, Mathiot, C, Caillot, D, Berthou, C, Benboubker, L, Garderet, L, Chaleteix, C, Traullé, C, Fuzibet, J G, Jaubert, J, Lamy, T, Casassus, P, Dib, M, Kolb, B, Dorvaux, V, Grosbois, B, Yakoub-Agha, I, Harousseau, J L, and Avet-Loiseau, H

Published
2007
Full Text
View/download PDF

32. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)

Author

Mateos, M.-V. Kumar, S. Dimopoulos, M.A. González-Calle, V. Kastritis, E. Hajek, R. De Larrea, C.F. Morgan, G.J. Merlini, G. Goldschmidt, H. Geraldes, C. Gozzetti, A. Kyriakou, C. Garderet, L. Hansson, M. Zamagni, E. Fantl, D. Leleu, X. Kim, B.-S. Esteves, G. Ludwig, H. Usmani, S. Min, C.-K. Qi, M. Ukropec, J. Weiss, B.M. Rajkumar, S.V. Durie, B.G.M. San-Miguel, J.

Abstract

Smoldering multiple myeloma (SMM) is an asymptomatic precursor state of multiple myeloma (MM). Recently, MM was redefined to include biomarkers predicting a high risk of progression from SMM, thus necessitating a redefinition of SMM and its risk stratification. We assembled a large cohort of SMM patients meeting the revised IMWG criteria to develop a new risk stratification system. We included 1996 patients, and using stepwise selection and multivariable analysis, we identified three independent factors predicting progression risk at 2 years: serum M-protein >2 g/dL (HR: 2.1), involved to uninvolved free light-chain ratio >20 (HR: 2.7), and marrow plasma cell infiltration >20% (HR: 2.4). This translates into 3 categories with increasing 2-year progression risk: 6% for low risk (38%; no risk factors, HR: 1); 18% for intermediate risk (33%; 1 factor; HR: 3.0), and 44% for high risk (29%; 2–3 factors). Addition of cytogenetic abnormalities (t(4;14), t(14;16), +1q, and/or del13q) allowed separation into 4 groups (low risk with 0, low intermediate risk with 1, intermediate risk with 2, and high risk with ≥3 risk factors) with 6, 23, 46, and 63% risk of progression in 2 years, respectively. The 2/20/20 risk stratification model can be easily implemented to identify high-risk SMM for clinical research and routine practice and will be widely applicable. © 2020, The Author(s).

Published
2020

33. Results from a multicenter, noninterventional registry study for multiple myeloma patients who received stem cell mobilization regimens with and without plerixafor

Author

Morris, C., Chabannon, C., Masszi, T., Russell, N., Nahi, H., Kobbe, G., Krejci, M., Auner, H.W., Pohlreich, D., Hayden, P., Basak, G.W., Lenhoff, S., Schaap, N.P., Biezen, A. van, Knol, C., Iacobelli, S., Liu, Q., Celanovic, M., Garderet, L., Kroger, N., Morris, C., Chabannon, C., Masszi, T., Russell, N., Nahi, H., Kobbe, G., Krejci, M., Auner, H.W., Pohlreich, D., Hayden, P., Basak, G.W., Lenhoff, S., Schaap, N.P., Biezen, A. van, Knol, C., Iacobelli, S., Liu, Q., Celanovic, M., Garderet, L., and Kroger, N.

Abstract

Contains fulltext : 218311.pdf (Publisher’s version ) (Open Access), Plerixafor plus granulocyte-colony stimulating factor (G-CSF) enhances the mobilization of hematopoietic stem cells (HSCs) for collection and subsequent autologous hematopoietic stem cell transplantation (HSCT) in patients with multiple myeloma (MM). This international, multicenter, noninterventional registry study (NCT01362972), evaluated long-term outcomes for MM patients who received plerixafor versus other mobilization regimens. The comparisons were: G-CSF + plerixafor (G-CSF + P) versus G-CSF-; G-CSF + P versus G-CSF + chemotherapy (G-CSF + C); and G-CSF + P + C versus G-CSF + C. Propensity score matching was used to balance groups. Primary outcome measures were progression free survival (PFS), overall survival (OS), and cumulative incidence of relapse (CIR) after transplantation. After propensity matching, 77 versus 41 patients in the G-CSF + P versus G-CSF cohorts, 129 versus 129 in the G-CSF + P versus G-CSF + C cohorts, and 117 versus 117 in the G-CSF + P + C versus G-CSF + C cohorts were matched, respectively. Propensity score matching resulted in a smaller sample size and imbalances were not completely overcome. For both PFS and OS, the upper limits of the hazard ratio 95% confidence intervals exceeded prespecified boundaries; noninferiority was not demonstrated. CIR rates were higher in the plerixafor cohorts. G-CSF + P remains an option for the mobilization of HSCs in poor mobilizers with MM with no substantial differences in PFS, OS, and CIR in comparison with other regimens.

Published
2020

34. Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network

Author

Ludwig, H. (Heinz), Boccadoro, M. (Mario), Moreau, P., San-Miguel, J. (Jesus), Cavo, M. (Michele), Pawlyn, C. (Charlotte), Zweegman, S. (Sonja), Facon, T. (Thierry), Driessen, C. (Christoph), Hajek, R. (Roman), Dimopoulos, M.A. (Melitios A.), Gay, F. (Francesca), Avet-Loiseau, H., Terpos, E. (Evangelos), Zojer, N. (Niklas), Mohty, M. (Mohamad), Mateos, M.V., Einsele, H. (Hermann), Delforge, M. (Michel), Caers, J. (Jo), Weisel, K. (Katja), Jackson, G. (Graham), Garderet, L. (Laurent), Engelhardt, M. (Monika), Donk, N.W.C.J. (Niels) van de, Leleu, X., Goldschmidt, H. (Hartmut), Beksaç, M. (Meral), Nijhof, I. (Inger), Abildgaard, N. (Niels), Bringhen, S. (Sara), Sonneveld, P. (Pieter), Ludwig, H. (Heinz), Boccadoro, M. (Mario), Moreau, P., San-Miguel, J. (Jesus), Cavo, M. (Michele), Pawlyn, C. (Charlotte), Zweegman, S. (Sonja), Facon, T. (Thierry), Driessen, C. (Christoph), Hajek, R. (Roman), Dimopoulos, M.A. (Melitios A.), Gay, F. (Francesca), Avet-Loiseau, H., Terpos, E. (Evangelos), Zojer, N. (Niklas), Mohty, M. (Mohamad), Mateos, M.V., Einsele, H. (Hermann), Delforge, M. (Michel), Caers, J. (Jo), Weisel, K. (Katja), Jackson, G. (Graham), Garderet, L. (Laurent), Engelhardt, M. (Monika), Donk, N.W.C.J. (Niels) van de, Leleu, X., Goldschmidt, H. (Hartmut), Beksaç, M. (Meral), Nijhof, I. (Inger), Abildgaard, N. (Niels), Bringhen, S. (Sara), and Sonneveld, P. (Pieter)

Abstract

Vaccination is one of the most successful medical interventions that has saved the life of millions of peo

Published
2020
Full Text
View/download PDF

35. Recent Advancements in Hematology: Knowledge, Methods and Dissemination

Author

Fitzgibbon, J, Busca, A, Gloghini, A, López-Guillermo, A, Orazi, A, Carlo-Stella, C, Andrès, E, Van Breda, E, Busti, F, Garderet, L, Martini, M, Dolcetti, R, De Rosa, S, Siragusa, S, Marafioti, T, Carbone, A, Fitzgibbon, J, Busca, A, Gloghini, A, López-Guillermo, A, Orazi, A, Carlo-Stella, C, Andrès, E, Van Breda, E, Busti, F, Garderet, L, Martini, M, Dolcetti, R, De Rosa, S, Siragusa, S, Marafioti, T, and Carbone, A

Abstract

Communication in the field of biomedical research today involves professionals of numerous backgrounds, including researchers, doctors, public administrators, politicians, and health journalists [...]

Published
2020

36. Recent Advancements in Hematology: Knowledge, Methods and Dissemination, Part 1

Author

Fitzgibbon, J, Park, S, Cook, G, Paiva, B, Gloghini, A, Van Breda, E, Busti, F, Garderet, L, Dolcetti, R, Robin, M, Martino, R, Busca, A, Sabbah, M, De Rosa, S, Martini, M, Onida, F, Aucouturier, P, Schjesvold, F, Minvielle, S, Mazzucato, M, Terragna, C, Delforge, M, Harrison, C, Carbone, A, Fitzgibbon, J, Park, S, Cook, G, Paiva, B, Gloghini, A, Van Breda, E, Busti, F, Garderet, L, Dolcetti, R, Robin, M, Martino, R, Busca, A, Sabbah, M, De Rosa, S, Martini, M, Onida, F, Aucouturier, P, Schjesvold, F, Minvielle, S, Mazzucato, M, Terragna, C, Delforge, M, Harrison, C, and Carbone, A

Abstract

Recent Advancements in Hematology: Knowledge, Methods and Dissemination is a series of editorials which is published on a biannual basis by the editorial board of the journal Bloods [...]

Published
2020

37. Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma

Author

Leleu, X, Fouquet, G, Hebraud, B, Roussel, M, Caillot, D, Chrétien, M L, Arnulf, B, Szalat, R, Garderet, L, Benajiba, L, Pegourie, B, Regny, C, Royer, B, Caulier, A, Stoppa, A M, Garciaz, S, Touzeau, C, Chaleteix, C, Fermand, J P, Loiseau, H A, Facon, T, Attal, M, and Moreau, P

Published
2013
Full Text
View/download PDF

39. Prophylaxis and treatment of graft-versus-host disease: EBMT - ELN working group recommendations for a standardized practice: 296

Author

Ruutu, T., Gratwohl, A., de Witte, T., Apperley, J., Bacigalupo, A., Dazzi, F., Dreger, P., Duarte, R. F., Finke, J., Garderet, L., Greinix, H. T., Holler, E., Kröger, N., Lawitschka, A., Mohty, M., Nagler, A., Passweg, J., Ringdén, O., Socié, G., Sierra, J., Stankevich, J., Sureda, A., Wiktor-Jedrzejczak, W., Madrigal, A., and Niederwieser, D.

Published
2013

41. Tandem autologous/reduced-intensity allogeneic stem cell transplantation versus autologous transplantation in multiple myeloma - update of the EBMT-NMAM2000 study at 96 months median follow-up: 197

Author

Gahrton, G., Iacobelli, S., Björkstrand, B., Hegenbart, U., Gruber, A., Greinix, H., Volin, L., Narni, F., Carella, A., Beksac, M., Bosi, A., Milone, G., Corradini, P., Schönland, S., Friberg, K., van Biezen, A., Goldschmidt, H., de Witte, T., Morris, C., Niederwieser, D., Garderet, L., and Kröger, N.

Published
2013

42. Higher probability of survival in complete remission following tandem autologous/reduced-intensity allogeneic transplantation compared to autologous transplantation alone in the NMAM2000 multiple myeloma trial as estimated by multistate models: O158

Author

Iacobelli, S., De Wreede, L., Björkstrand, B., Hegenbart, U., Gruber, A., Greinix, H., Volin, L., Narni, F., Carella, A. M., Beksac, M., Bosi, A., Milone, G., Corradini, P., Schönland, S., Friberg, K., van Biezen, A., Goldschmidt, H., de Witte, T., Morris, C., Niederwieser, D., Garderet, L., Kröger, N., and Gahrton, G.

Published
2013

48. Bortezomib (Velcade)-thalidomide-dexamethasone is superior to thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: 0117

Author

Garderet, L., Iacobelli, S., Moreau, P., Dib, M., Caillot, D., Niederwieser, D., Masszi, T., Fontan, J., Michallet, M., Gratwohl, A., Milone, G., Doyen, C., Pegourie, B., Hajek, R., Casassus, P., Kolb, B., Chaleteix, C., Hertenstein, B., Onida, F., Ludwig, H., Vekemans, M. C., Ketterer, N., Daguenel, A., Koenecke, C., Gorin, N.-C., Harousseau, J.-L., de Witte, T., Morris, C., and Gahrton, G.

Published
2011

49. Corrigendum: Second primary malignancies in multiple myeloma: an overview and IMWG consensus

Author

Musto, P, Anderson, K. C, Attal, M, Richardson, P. G, Badros, A, Hou, J, Comenzo, R, Du, J, Durie, B. G. M, San Miguel, J, Einsele, H, Chen, W. M, Garderet, L, Pietrantuono, G, Hillengass, J, Kyle, R. A, Moreau, P, Lahuerta, J. J, Landgren, O, Ludwig, H, Larocca, A, Mahindra, A, Cavo, M, Mazumder, A, McCarthy, P. L, Nouel, A, Rajkumar, S. V, Reiman, A, Riva, E, Sezer, O, Terpos, E, Turesson, I, Usmani, S, Weiss, B. M, Palumbo, A., Musto, P, Anderson, K. C, Attal, M, Richardson, P. G, Badros, A, Hou, J, Comenzo, R, Du, J, Durie, B. G. M, San Miguel, J, Einsele, H, Chen, W. M, Garderet, L, Pietrantuono, G, Hillengass, J, Kyle, R. A, Moreau, P, Lahuerta, J. J, Landgren, O, Ludwig, H, Larocca, A, Mahindra, A, Cavo, M, Mazumder, A, Mccarthy, P. L, Nouel, A, Rajkumar, S. V, Reiman, A, E, Riva, Sezer, O, Terpos, E, Turesson, I, Usmani, S, Weiss, B. M, and Palumbo, A.

Subjects
NA
Abstract

Erratum to: Annals of Oncology, Volume 28, Issue 2, 1 February 2017, Pages 228–245, https://doi.org/10.1093/annonc/mdw606

Published
2018

50. Bortezomib (Velcade®)-Thalidomide-Dexamethasone (VTD) versus Thalidomide-Dexamethasone to treat multiple myeloma (MM) patients progressing or relapsing after autologous transplantation: the MMVAR trial, a study from the myeloma subcommittee of the Chronic Leukemia Working Party of the EBMT: 221

Author

Garderet, L., Iacobelli, S., Moreau, P., Onida, F., Koenecke, C., Pabst, T., Doyen, C., Crawley, C., Hajek, R., Linkesch, W., Harousseau, J. L., Michallet, M., Doran, Z., de Witte, T., Niederwieser, D., Gahrton, G., and Morris, C.

Published
2009

Catalog

Books, media, physical & digital resources
See catalog results